Seeing all sides, and knowing what matters.
Sectors of Focus
Seeing all sides, and knowing what matters.
Sectors of Focus
Typical Transaction
- Sell-side M&A
- Capital raising
EXPERIENCE + UNDERSTANDING
The Bourne Partners investment banking team understands opportunities from every angle and we concentrate on what’s important to you.
block-legacy-sebela
Legacy Pharma Inc. is a pharmaceutical company that distributes established prescription pharmaceutical products.
SECTOR: Pharmaceuticals
YEAR: November 2024
DEAL SIZE: Undisclosed
MANDATE TYPE: Buy-Side M&A
block-nicox-soleus
Nicox is a pharmaceutical company focused on developing innovative treatments to preserve vision and enhance ocular health. Their lead product, NCX 470, targets glaucoma, a serious eye condition. Nicox is also advancing its pipeline with nitric oxide-donating molecules and partners with global companies to commercialize its treatments.
SECTOR: Biopharma
YEAR: October 2024
DEAL SIZE: $16.5 M
MANDATE TYPE: Royalty Monetization
block-nivagen-medisource-himsandhers
Nivagen specializes in the development, acquisition, and sales of generic prescription and over-the-counter products for the North American market, emphasizing high quality and affordability through global FDA-approved manufacturing partnerships. Nivagen also has a state-of-the-art sterile injectables facility in California, where it will plan to manufacture its portfolio and pipeline of injectable ANDAs and 505(b)(2)s. Nivagen’s MedisourceRx business unit is a 503B outsourcing facility, supplying clinics and physician offices with high quality compounded wellness products.
SECTOR: Compounding
YEAR: September 2024
DEAL SIZE: Undisclosed
MANDATE TYPE: Sell-Side M&A Advisory
block-reverba-424-6degrees
For over two decades, Reverba has been collaborating with biopharmaceutical companies to enhance their rapport with patients, recognizing that these connections represent their most valuable asset. Reverba understands that to enhance the patient experience and foster company growth, it is essential to engage healthcare consumers on their terms. This perspective guides Reverba in empowering patients to express themselves while equipping biopharmaceutical companies with the tools to listen attentively.
SECTOR: Pharmaceuticals
YEAR: April 2024
DEAL SIZE: Undisclosed
MANDATE TYPE: Buy-Side M&A Advisory
block-ai-newrhein
American Injectables is a US-based sterile injectable manufacturer focused on ready-to-use pre-filled syringes and vials. The company serves as an outsourced contract development and manufacturing partner for pharmaceutical companies across the globe.
SECTOR: Pharma Services
YEAR: February 2024
DEAL SIZE: Undisclosed
MANDATE TYPE: Financing
block-clincierge-greenphire-tb
Clincierge reduces the emotional, logistical, and financial barriers to clinical trial participation, enabling patients to access life-changing and potentially lifesaving new treatment options. Their high-touch patient concierge services include but are not limited to, individualized air and rail ticketing, hotel and housing accommodations, payment and reimbursement processes, and ongoing patient, family, and caregiver support. Their services reduce the emotional and financial stressors related to travel and out-of-pocket expenses related to clinical trial participation. They address unique patient and caregiver needs, and the many demands complex trial designs place on participants and their families, building custom solutions to specific study-related problems.
SECTOR: Pharmaceuticals
YEAR: January 2024
DEAL SIZE: Undisclosed
MANDATE TYPE: Sell-Side M&A Advisory
block-afton-acp
Afton Scientific is a contract, development and manufacturing organization (“CDMO”) that specializes in small-batch filling of injectables from clinical trials to approved commercial drugs. Afton has provided reliable pharmaceutical services and lasting relationships within the industry for over 30 years. Utilizing 35,000 square feet of manufacturing, lab, warehouse, and administrative space, Afton provides custom, innovative solutions for clinical to commercial sterile manufacturing, packaging and labeling, analytical and micro lab services, and pharmaceutical support services.
SECTOR: Pharmaceuticals
YEAR: January 2024
DEAL SIZE: Undisclosed
MANDATE TYPE: Sell-Side M&A Advisory
block-summit-kindeva
Summit Biosciences is a specialized pharmaceutical company focused on developing, manufacturing and commercializing generic and innovative nasal spray medicines. Summit collaborates on the development of products with their clients and manufactures at commercial scale for the US and European markets.
SECTOR: Pharmaceuticals
YEAR: January 2024
DEAL SIZE: Undisclosed
MANDATE TYPE: Sell-Side M&A Advisory
block-medivant-1315
Medivant Healthcare is a pharmaceutical manufacturing and 503B hospital outsourcing company, specializing in the production of single-dose injectable medications aimed at addressing drug shortages and improving patient care efficiency.
SECTOR: Pharmaceutical and 503B
YEAR: September 2023
DEAL SIZE: Undisclosed
MANDATE TYPE: Growth Equity
block-contipi-indegene
ConTIPI Medical Ltd provides non-surgical and disposable vaginal solutions for women with various Pelvic Floor Disorders (PFDs). ConTIPI’s first device for stress urinary incontinence (SUI), the Impressa device, was acquired by Kimberly Clark Worldwide and is available for sale. ConTIPI’s following innovation is the ProVate Device, intended to manage Pelvic Organ Prolapse (POP) in women.
SECTOR: Medical Device; Tech-Enabled Services
YEAR: May 2023
DEAL SIZE: Undisclosed
MANDATE TYPE: Commercialization
block-contipi-capIP-GTP
ConTIPI Medical Ltd provides non-surgical and disposable vaginal solutions for women with various Pelvic Floor Disorders (PFDs). ConTIPI’s first device for stress urinary incontinence (SUI), the Impressa device, was acquired by Kimberly Clark Worldwide and is available for sale. ConTIPI’s following innovation is the ProVate Device, intended to manage Pelvic Organ Prolapse (POP) in women.
SECTOR: Medical Device
YEAR: May 2023
DEAL SIZE: $40,000,000
MANDATE TYPE: Capital Raise
block-uphealth-medquest
SECTOR: Pharmacy Services
YEAR: February 2023
DEAL SIZE: $56,000,000
MANDATE TYPE: Sell-Side Advisory
CONNECTION + COLLABORATION
We collaborate with industry stakeholders and draw on strong relationships on both the advisory and strategic capital sides.
And we don’t stop until the deal is done.